专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US08216570B2 TES7 and antibodies that bind thereto 有权
标题翻译： TES7和与其结合的抗体
公开(公告)号：US08216570B2
公开(公告)日：2012-07-10
申请号：US12724564
申请日：2010-03-16
申请人： Jennie P. Mather , Tony W. Liang
发明人： Jennie P. Mather , Tony W. Liang
IPC分类号： A61K39/395
CPC分类号： G01N33/57484 , A61K2039/505 , C07K16/2827 , C07K16/30 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77
摘要： The invention provides the identification and characterization of a disease and cancer-associated antigen, TES7. The invention also provides a family of monoclonal antibodies that bind to antigen TES7, methods of diagnosing and treating various human cancers and diseases with TES7.
摘要翻译：本发明提供疾病和癌症相关抗原TES7的鉴定和表征。本发明还提供了结合抗原TES7的单克隆抗体家族，用TES7诊断和治疗各种人类癌症和疾病的方法。

32. 发明授权

US08187594B2 Transferrin receptor antibodies 有权
标题翻译：转铁蛋白受体抗体
公开(公告)号：US08187594B2
公开(公告)日：2012-05-29
申请号：US12483774
申请日：2009-06-12
申请人： Jennie P. Mather , Penelope E. Roberts , Ronghao Li
发明人： Jennie P. Mather , Penelope E. Roberts , Ronghao Li
IPC分类号： A61K39/395 , A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/2881 , A61K39/39533 , A61K2039/505 , C07K16/2863 , C07K2317/77 , Y10S530/808 , Y10S530/809 , A61K2300/00
摘要： The invention provides further characterization of the disease and cancer-associated antigen, transferrin receptor. The invention also provides a novel family of antibodies that bind to the transferrin receptor, methods of diagnosing and treating various human cancers and diseases that express transferrin receptor.
摘要翻译：本发明提供了疾病和癌症相关抗原转铁蛋白受体的进一步表征。本发明还提供了结合转铁蛋白受体的新型抗体家族，诊断和治疗表达转铁蛋白受体的各种人类癌症和疾病的方法。

33. 发明授权

US08133982B2 FcγRIIB specific antibodies and methods of use thereof 有权
标题翻译： FcγRIIB特异性抗体及其使用方法
公开(公告)号：US08133982B2
公开(公告)日：2012-03-13
申请号：US12349876
申请日：2009-01-07
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： C07K16/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer (preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), autoimmune disease, inflammatory disease or IgE-mediated allergic disorder. The present invention also encompasses the use of a humanized FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention with a vaccine composition.
摘要翻译：本发明涉及以比所述抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段和变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导平衡失去相关的任何疾病（例如癌症（优选B细胞恶性肿瘤，特别是B细胞慢性淋巴细胞性白血病或非 - 霍奇金淋巴瘤），自身免疫性疾病，炎性疾病或IgE介导的过敏性疾病。本发明还包括与其它癌症疗法组合的人源化FcγRIIB抗体或其抗原结合片段的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过用疫苗组合物施用本发明的人源化抗体来增强疫苗组合物的功效的方法。

34. 发明申请

US20110081347A1 Antibodies with Altered Binding to FcRn and Methods of Using Same 审中-公开
标题翻译：具有改变与FcRn结合的抗体及其使用方法
公开(公告)号：US20110081347A1
公开(公告)日：2011-04-07
申请号：US12995545
申请日：2009-06-04
申请人： Sergey Gorlatov
发明人： Sergey Gorlatov
IPC分类号： A61K39/395 , C07K16/28 , C07K16/10 , C07K16/12 , C07K16/08 , C07H21/00 , A61P35/00 , A61P31/00
CPC分类号： C07K16/30 , A61K39/395 , A61K39/39558 , A61K45/06 , C07K16/00 , C07K16/18 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/72 , C07K2317/94
摘要： This invention relates to antibodies with altered binding to FcRn, and particularly antibodies having enhanced binding to FcRn and/or enhanced serum half-lives. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease.
摘要翻译：本发明涉及具有改变的结合FcRn的抗体，特别是具有增强的与FcRn结合和/或增强的血清半衰期的抗体。本发明还涉及将抗体及其组合物用于诊断，预后和治疗诸如癌症，自身免疫性疾病，炎症性疾病和感染性疾病的疾病的方法。

35. 发明申请

US20100015142A1 METHODS FOR THE TREATMENT OF LADA AND OTHER ADULT- ONSET AUTOIMMUNE USING IMMUNOSUPPRESSIVE MONOCLONAL ANTIBODIES WITH REDUCED TOXICITY 审中-公开
标题翻译：使用具有降低毒性的免疫抑制性单克隆抗体治疗LADA和其他成年人自身免疫的方法
公开(公告)号：US20100015142A1
公开(公告)日：2010-01-21
申请号：US12519610
申请日：2007-12-13
申请人： Scott Koenig
发明人： Scott Koenig
IPC分类号： A61K39/395 , A61P3/10
CPC分类号： C07K16/2809 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/71
摘要： The present invention provides methods of treating, preventing or ameliorating the symptoms of Latent Autoimmune Diabetes in Adults (LADA) and adult-onset type 1 diabetes through the use of anti-human CD3 antibodies. In particular, in invention provides methods of preventing or delaying insulin requirement in patients diagnosed with LADA. The methods of the invention provide for administration of antibodies that specifically bind the epsilon subunit within the human CD3 complex. Such antibodies modulate the T cell receptor/alloantigen interaction and, thus, regulate the T cell mediated cytotoxicity associated with autoimmune disorders. Additionally, the invention provides for modification of the anti-human CD3 antibodies such that they exhibit reduced or eliminated effector function and T cell activation as compared to non-modified anti-human CD3 antibodies.
摘要翻译：本发明提供了通过使用抗人CD3抗体来治疗，预防或改善成人潜伏性自身免疫性糖尿病（LADA）和成人发病1型糖尿病的症状的方法。特别地，本发明提供了在诊断为LADA的患者中预防或延迟胰岛素需求的方法。本发明的方法提供了特异性结合人CD3复合物内的ε亚基的抗体的施用。这种抗体调节T细胞受体/同种异体抗原相互作用，因此调节与自身免疫疾病相关的T细胞介导的细胞毒性。另外，本发明提供抗人CD3抗体的修饰，使得它们与非修饰的抗人CD3抗体相比表现出降低或消除的效应子功能和T细胞活化。

36. 发明申请

US20090324593A1 Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof 审中-公开
标题翻译：针对西尼罗河病毒的人源化抗体及其治疗和预防用途
公开(公告)号：US20090324593A1
公开(公告)日：2009-12-31
申请号：US12457447
申请日：2009-06-11
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395 , C07K16/00 , C12Q1/70 , A61P31/12
CPC分类号： C07K16/1081 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , G01N33/56983 , G01N2333/18 , G01N2469/20 , Y02A50/386 , Y02A50/388 , Y02A50/394 , Y02A50/396 , Y02A50/53 , Y02A50/60
摘要： The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV. antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
摘要翻译：本发明涉及包含人源化抗体或其片段的组合物，其免疫特异性结合黄病毒，特别是西尼罗病毒（WNV）的一种或多种抗原，以及用于预防，治疗或改善与黄病毒特别是西尼罗病毒有关的症状的方法利用所述组合物的病毒（WNV）感染。特别地，本发明涉及用于预防，治疗或改善与WNV感染相关的症状的方法，所述方法包括向人受体施用有效量的一种或多种免疫特异性结合WNV抗原的人源化抗体或其片段。本发明还涉及包含免疫特异性结合WNV的人源化抗体或其片段的可检测或诊断组合物。抗原和利用所述组合物检测或诊断WNV感染的方法。

37. 发明申请

US20090202537A1 FcGammaRIIB Specific Antibodies and Methods of Use Thereof 有权
标题翻译： FcGammaRIIB特异性抗体及其使用方法
公开(公告)号：US20090202537A1
公开(公告)日：2009-08-13
申请号：US12349876
申请日：2009-01-07
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395 , C07K16/30 , C07H21/00 , A61P35/00
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer (preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma), autoimmune disease, inflammatory disease or IgE-mediated allergic disorder. The present invention also encompasses the use of a humanized FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention with a vaccine composition.
摘要翻译：本发明涉及以与抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段及其变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导平衡失去相关的任何疾病（例如癌症（优选B细胞恶性肿瘤，特别是B细胞慢性淋巴细胞性白血病或非 - 霍奇金淋巴瘤），自身免疫性疾病，炎性疾病或IgE介导的过敏性疾病。本发明还包括与其它癌症疗法组合的人源化FcγRIIB抗体或其抗原结合片段的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过用疫苗组合物施用本发明的人源化抗体来增强疫苗组合物的功效的方法。

38. 发明授权

US07572456B2 Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof 失效
标题翻译：针对西尼罗病毒的人源化抗体及其治疗和预防用途
公开(公告)号：US07572456B2
公开(公告)日：2009-08-11
申请号：US11226886
申请日：2005-09-13
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/00 , A61K39/12 , A61Q5/00 , C12P7/24 , C12P7/52 , C12N5/16 , C12N11/10
CPC分类号： C07K16/1081 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , G01N33/56983 , G01N2333/18 , G01N2469/20 , Y02A50/386 , Y02A50/388 , Y02A50/394 , Y02A50/396 , Y02A50/53 , Y02A50/60
摘要： The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions.
摘要翻译：本发明涉及包含人源化抗体或其片段的组合物，其免疫特异性结合黄病毒，特别是西尼罗病毒（WNV）的一种或多种抗原，以及用于预防，治疗或改善与黄病毒特别是西尼罗病毒有关的症状的方法利用所述组合物的病毒（WNV）感染。特别地，本发明涉及用于预防，治疗或改善与WNV感染相关的症状的方法，所述方法包括向人类受试者施用有效量的一种或多种免疫特异性结合WNV抗原的人源化抗体或其片段。本发明还涉及包含免疫特异性结合WNV抗原的人源化抗体或其片段的可检测或诊断组合物，以及利用所述组合物检测或诊断WNV感染的方法。

39. 发明申请

US20090162353A1 Compositions for the Prevention and Treatment of Smallpox 有权
标题翻译：预防和治疗天花的成分
公开(公告)号：US20090162353A1
公开(公告)日：2009-06-25
申请号：US12338142
申请日：2008-12-18
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： A61K39/395
CPC分类号： C07K16/081 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/31 , C07K2317/55 , C07K2317/76
摘要： The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.
摘要翻译：本发明涉及用于预防和治疗天花的改进的组合物，特别是涉及使用含有抗体的组合物，所述组合物含有与在天花病毒MV形式上发现的表位结合的抗体，以及结合表位上发现的表位的抗体 EV形式的天花病毒。本发明涉及这样的组合物，特别是涉及非血液衍生的抗体组合物，例如嵌合或人源化抗体，以及它们用于在天花病毒感染风险或出现天花的个体赋予对天花感染的被动免疫的方法。

40. 发明授权

US07521542B2 Humanized FcγRIIB-specific antibodies and methods of use thereof 有权
标题翻译：人源化FcγRIIB特异性抗体及其使用方法
公开(公告)号：US07521542B2
公开(公告)日：2009-04-21
申请号：US11126978
申请日：2005-05-10
申请人： Leslie S. Johnson , Ling Huang
发明人： Leslie S. Johnson , Ling Huang
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , G01N33/574 , G01N33/53 , C12P21/04 , C07H21/04
CPC分类号： C07K16/283 , A61K2039/505 , C07K2317/24 , C07K2317/34
摘要： The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
摘要翻译：本发明涉及以与抗体结合FcγRIIA更大的亲和力结合人FcγRIIB的人源化FcγRIIB抗体，其片段及其变体。本发明包括本发明的人源化抗体用于治疗与Fc受体介导的信号传导的平衡丧失有关的任何疾病（例如癌症，自身免疫性和炎症性疾病）的用途。本发明提供了通过施用本发明的人源化抗体来增强治疗性抗体的治疗效果以增强治疗性抗体的效应子功能的方法。本发明还提供了通过施用本发明的人源化抗体来增强疫苗组合物的功效的方法。本发明包括治疗自身免疫疾病的方法和用于消除表达FcγRIIB的癌细胞的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式